COVID-19 and Cutaneous Squamous Cell Carcinoma-Impact of the Pandemic on Unequal Access to Healthcare.

Marko Jović, Milana Marinković, Branko Suđecki, Milana Jurišić, Zoran Bukumirić, Milan Jovanović, Milan Stojičić, Jelena Jeremić
Author Information
  1. Marko Jović: Clinic for Burns, Plastic and Reconstructive Surgery, University Clinical Center of Serbia, 11000 Belgrade, Serbia.
  2. Milana Marinković: Clinic for Burns, Plastic and Reconstructive Surgery, University Clinical Center of Serbia, 11000 Belgrade, Serbia. ORCID
  3. Branko Suđecki: Clinic for Burns, Plastic and Reconstructive Surgery, University Clinical Center of Serbia, 11000 Belgrade, Serbia. ORCID
  4. Milana Jurišić: Clinic for Burns, Plastic and Reconstructive Surgery, University Clinical Center of Serbia, 11000 Belgrade, Serbia. ORCID
  5. Zoran Bukumirić: Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia. ORCID
  6. Milan Jovanović: Clinic for Burns, Plastic and Reconstructive Surgery, University Clinical Center of Serbia, 11000 Belgrade, Serbia.
  7. Milan Stojičić: Clinic for Burns, Plastic and Reconstructive Surgery, University Clinical Center of Serbia, 11000 Belgrade, Serbia. ORCID
  8. Jelena Jeremić: Clinic for Burns, Plastic and Reconstructive Surgery, University Clinical Center of Serbia, 11000 Belgrade, Serbia.

Abstract

Most skin tumors are not fatal, but if not treated in a timely manner, they can lead to significant morbidity. Due to the COVID-19 pandemic and in order to create more capacities for the treatment of COVID-19-positive patients as well as to contain the spread of the virus, the healthcare system was reorganized worldwide, leading to decreased access to preventive screening programs. The aim of this study was to evaluate the impact of the pandemic on healthcare accessibility to cutaneous squamous cell carcinoma patients in Serbia. This retrospective study was conducted at the Clinic for Burns, Plastic, and Reconstructive Surgery, University Clinical Center of Serbia in Belgrade. Patient demographics and pathohistological findings of tumors of patients living in and outside the capital in the period before, during, and after the pandemic were compared. The two groups did not show any differences regarding the largest tumor diameter prior and during the pandemic; however, this difference became extremely noticeable after the pandemic (15 mm vs. 27 mm; < 0.001). While cSCCs are commonly slow-growing tumors, the impact of the COVID-19 pandemic is not negligible. This study found a population at a significant risk of cSCC metastasis, with additional evidence likely to emerge in the upcoming years.

Keywords

References

  1. J Cutan Aesthet Surg. 2020 Oct-Dec;13(4):349-352 [PMID: 33911420]
  2. N Engl J Med. 2020 Jul 2;383(1):88-89 [PMID: 32343497]
  3. Healthcare (Basel). 2022 May 09;10(5): [PMID: 35628008]
  4. CA Cancer J Clin. 2021 May;71(3):209-249 [PMID: 33538338]
  5. J Am Acad Dermatol. 2010 Sep;63(3):404-11 [PMID: 20598396]
  6. J Plast Reconstr Aesthet Surg. 2022 Aug;75(8):2831-2870 [PMID: 35817712]
  7. Eur Heart J Qual Care Clin Outcomes. 2021 Jan 25;7(1):18-27 [PMID: 33151274]
  8. JAMA Dermatol. 2016 Apr;152(4):419-28 [PMID: 26762219]
  9. Dermatol Clin. 2021 Oct;39(4):627-637 [PMID: 34556252]
  10. J Eur Acad Dermatol Venereol. 2016 Apr;30 Suppl 3:5-11 [PMID: 26995016]
  11. Plast Reconstr Surg. 2013 Dec;132(6):1631-1643 [PMID: 24281589]
  12. Br J Surg. 2020 Sep;107(10):1250-1261 [PMID: 32350857]
  13. JAMA Dermatol. 2019 Mar 1;155(3):298-306 [PMID: 30484823]
  14. Front Oncol. 2022 Sep 23;12:966011 [PMID: 36212498]
  15. Cancer. 2020 Sep 1;126(17):3900-3906 [PMID: 32478867]
  16. Int J Environ Res Public Health. 2022 Dec 14;19(24): [PMID: 36554683]
  17. Healthcare (Basel). 2023 Feb 21;11(5): [PMID: 36900640]
  18. Acta Derm Venereol. 2021 Aug 25;101(8):adv00525 [PMID: 34396424]
  19. Skin Health Dis. 2023 Mar 10;3(2):e224 [PMID: 37013119]
  20. J Am Acad Dermatol. 2022 Aug;87(2):255-268 [PMID: 35176397]
  21. Br J Dermatol. 2022 Aug;187(2):196-202 [PMID: 35141890]
  22. N Engl J Med. 2001 Mar 29;344(13):975-83 [PMID: 11274625]
  23. J Plast Reconstr Aesthet Surg. 2022 Sep;75(9):3616-3621 [PMID: 35918285]
  24. Biomedicines. 2021 Feb 09;9(2): [PMID: 33572373]
  25. Br J Surg. 2020 Nov;107(12):e598-e600 [PMID: 32936450]
  26. Healthcare (Basel). 2023 Feb 17;11(4): [PMID: 36833145]
  27. Br J Dermatol. 2020 Feb;182(2):468-476 [PMID: 31220341]
  28. J Invest Dermatol. 2017 Nov;137(11):2309-2315 [PMID: 28736229]
  29. Surgeon. 2021 Oct;19(5):e207-e212 [PMID: 33257272]
  30. World J Otorhinolaryngol Head Neck Surg. 2016 Aug 01;2(2):136-140 [PMID: 29204558]
  31. Int J Dermatol. 2021 Jul;60(7):860-863 [PMID: 33665815]
  32. Trop Med Int Health. 2021 Oct;26(10):1177-1188 [PMID: 34219346]
  33. Cancer Med. 2021 Jul;10(14):4905-4922 [PMID: 34105887]
  34. Eur Heart J. 2020 Jun 7;41(22):2083-2088 [PMID: 32412631]
  35. ESMO Open. 2020 Sep;5(5):e000947 [PMID: 32978251]
  36. Int J Dermatol. 2020 Aug;59(8):e269-e270 [PMID: 32501536]
  37. MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):343-346 [PMID: 32214079]
  38. Healthcare (Basel). 2022 Nov 21;10(11): [PMID: 36421653]

Word Cloud

Created with Highcharts 10.0.0pandemichealthcaretumorsCOVID-19patientsstudyskinsignificantimpactaccessibilitycutaneoussquamouscellcarcinomaSerbiammfataltreatedtimelymannercanleadmorbidityDueordercreatecapacitiestreatmentCOVID-19-positivewellcontainspreadvirussystemreorganizedworldwideleadingdecreasedaccesspreventivescreeningprogramsaimevaluateretrospectiveconductedClinicBurnsPlasticReconstructiveSurgeryUniversityClinicalCenterBelgradePatientdemographicspathohistologicalfindingslivingoutsidecapitalperiodcomparedtwogroupsshowdifferencesregardinglargesttumordiameterpriorhoweverdifferencebecameextremelynoticeable15vs27<0001cSCCscommonlyslow-growingnegligiblefoundpopulationriskcSCCmetastasisadditionalevidencelikelyemergeupcomingyearsCutaneousSquamousCellCarcinoma-ImpactPandemicUnequalAccessHealthcaresystemslockdownpublichealth

Similar Articles

Cited By